INSTOR reports a full spectrum of clinical outcomes, with or without single- or multi-factorial risk adjustment, for patients treated with Intravenous tissue Plasminogen Activator (IV tPA) therapy only, as well as Endovascular Therapy (EVT) alone or in combination with IV tPA. The only national registry that tracks and reports the internationally accepted benchmark for clinical outcomes, the 90-day Modified Rankin Score (mRS), INSTOR provides multiple other clinical outcomes performance measures that are unique to this registry.
All outcomes for treatment of patients with IV tPA are presented in one report, including single-factor risk-adjustment and complications.
In depth analysis of all aspects of combination IV tPA and EVT, including clinical outcomes, procedural success (measured by the TICI score), and complications, is provided in one report. Results are compared to an anonymous national aggregate.
INSTOR is unique in its ability to provide risk-adjusted subgroup analysis of clinical outcomes based upon initial severity of stroke for patients treated with IV tPA.
Clinical outcomes are known to depend greatly on the site of the vascular occlusion. Facilitating point and click data entry of this information (from CTA or catheter angiogram), INSTOR tracks this vital information and provides institutional results which can be compared to an anonymous national aggregate.